Enzo Biochem, Inc.
ENZ
$1.09
-$0.02-1.80%
| 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | 01/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 346.55% | 140.15% | -4.85% | -120.99% | -111.26% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 346.55% | 140.15% | -4.85% | -120.99% | -111.26% |
| Cost of Revenue | 504.22% | 125.78% | 1.47% | -109.78% | -107.24% |
| Gross Profit | 260.62% | 166.22% | -13.88% | -136.14% | -116.15% |
| SG&A Expenses | 188.31% | 69.94% | 25.00% | -69.53% | -77.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 481.13% | 85.29% | 17.30% | -89.93% | -92.02% |
| Operating Income | -1.21% | -44.35% | -65.72% | -350.34% | -759.40% |
| Income Before Tax | 1.25% | -8.43% | -23.03% | -417.44% | -7,970.33% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 1.25% | -8.43% | -23.03% | -417.44% | -7,970.33% |
| Earnings from Discontinued Operations | 507.62% | 1,040.18% | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 192.41% | 191.46% | 211.10% | -594.74% | -11,847.33% |
| EBIT | -1.21% | -44.35% | -65.72% | -350.34% | -759.40% |
| EBITDA | -6.65% | -58.38% | -82.27% | -547.33% | -21,479.79% |
| EPS Basic | 192.83% | 191.56% | 210.09% | -591.02% | -11,585.71% |
| Normalized Basic EPS | 2.63% | -20.80% | -40.72% | -236.01% | -479.92% |
| EPS Diluted | 192.50% | 191.12% | 208.76% | -544.34% | -13,844.23% |
| Normalized Diluted EPS | 2.63% | -20.80% | -40.72% | -237.04% | -482.17% |
| Average Basic Shares Outstanding | 2.29% | 1.52% | 0.90% | 0.67% | 0.49% |
| Average Diluted Shares Outstanding | 2.29% | 1.52% | 0.90% | 0.48% | 0.09% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
